000538 云南白药
2025/06 - 中期
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入21,257,1033.92%40,033,30139,111,29236,488,37336,373,919
减:营业总成本17,836,2863.55%35,206,79735,082,75032,087,16831,739,818
    其中:营业成本14,697,8681.63%28,864,76628,744,51826,883,48526,498,435
               财务费用(23,107)-82.17%(155,555)(259,244)(342,878)(258,281)
               资产减值损失(41,743)1,066.47%(91,231)(58,128)(664,339)(143,220)
公允价值变动收益70,0371,423.59%136,837123,566(619,903)(1,929,217)
投资收益839,62975.84%776,937779,011868,1981,044,401
    其中:对联营企业和合营企业的投资收益783,53054.65%774,280628,532732,233(21,100)
营业利润4,220,31614.92%5,711,6224,830,5063,371,2793,485,169
利润总额4,231,87215.25%5,684,7204,818,0123,377,0023,481,646
减:所得税费用587,27221.82%917,647695,451536,593683,986
净利润3,644,60014.25%4,767,0724,122,5612,840,4102,797,661
减:非控股权益11,689931.70%17,65728,779(160,716)(7,256)
股东净利润3,632,91113.93%4,749,4154,093,7823,001,1262,804,917

市场价值指针
每股收益 (元) *2.04013.97%2.6602.2901.9002.210
每股派息 (元) *1.019--2.3982.0771.5201.600
每股净资产 (元) *22.6462.63%21.76422.19421.42829.800
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容